Immunize

Hib Vaccine

search

Hib Vaccine, Haemophilus influenzae B Vaccine, ActHIB, Hiberix, PedvaxHIB

  • See Also
  1. Haemophilus Influenzae
  2. Primary Series
  • Indications
  1. Primary Series (Immunization Schedule in Children)
  2. Immunocompromised State
    1. Immunocompromised state requires additional Hib doses (esp. if age 12 to 59 months)
    2. Conditions required additional Hib Vaccine doses (see CDC guidelines)
      1. Chemotherapy or Radiation Therapy
      2. Hematopoietic Stem Cell Transplant
      3. Anatomic Asplenia or Functional Asplenia (e.g. Sickle Cell Anemia)
      4. Elective Splenectomy
      5. HIV Infection
      6. Immunoglobulin Deficiency or Early component complement deficiency
  • Mechanism
  1. Hib is a conjugated protein Vaccine
    1. Haemophilus Influenzae PRP Capsule Protein (Polyribitol Ribose Phosphate)
    2. Conjugated to one of the following immunogenic Proteins (activate T Lymphocytes)
      1. Mutated Diphtheria toxin Protein
      2. Neisseria Meningitidis outer membrane Protein
      3. Tetanus Toxoid
  • Medications
  1. Individual Vaccinations
    1. PRP-T (ActHIB or Hiberix)
    2. PRP-OMP (PedvaxHIB)
      1. Stronger immune response with first dose
      2. Preferred in high risk communities
        1. American Indian or Alaska native
        2. Asplenia or Immunosuppression
  2. Standard Combination agents (most common delivery for U.S. Primary Series)
    1. DTaP/IPV/PRP-T (Pentacel)
    2. PRP-OMP/HepB (Comvax)
  3. Other combinations (limited use)
    1. Hib/MenCY (Menhibrix)
  1. Dose 1: Age 2 months
  2. Dose 2: Age 4 months
  3. Dose 3: Age 6 months (dose 3 is skipped if using PedvaxHIB for all other 3 doses)
  4. Dose 4: Age 12 to 15 months
  • Efficacy
  1. See Haemophilus Influenzae
  2. Prior to 1985, 1 in 200 children contracted Hib, with Epiglottitis accounting for 15-30% of Hib Cases
    1. Previously Hib was most common cause of Meningitis and invasive disease <5 years old
    2. Other conditions beyond Meningitis and Epiglottitis included bacteremia, facial Cellulitis and Septic Arthritis
  3. Decreased Incidence by 95-99% since Hib Vaccination began in 1987 to 1989
    1. Adults also saw a significant drop in Hib cases, related to Herd Immunity when >75% vaccinated rates
  • Adverse Effects
  1. No serious side effects
  2. Fever
  3. Irritability
  4. References
    1. (1996) MMWR Morb Mortal Wkly Rep 45(No. RR-12):1-35 [PubMed]
  • Resources
  1. CDC Immunization Schedules (last accessed 10/28/2020)
    1. https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html
  • References
  1. Ackerman (2015) Am Fam Physician 92(6): 460-8 [PubMed]
  2. Briere (2014) MMWR Recomm Rep 63(RR-01):1-14 [PubMed]